Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | F13A1 | P00488 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.50 |
| ▸ | TGM1 | P22735 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL377565 | 0.90 | ALDH1A1 (0.68) | ALDH1A1NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL377564 | 0.90 | ALDH1A1 (0.68) | ALDH1A1NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL6154643 | 0.89 | ALDH1A1 (0.60) | ALDH1A1NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL1704680 | 0.88 | ALDH1A1 (0.59) | ALDH1A1NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL377801 | 0.87 | ALDH1A1 (0.75) | ALDH1A1NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL377914 | 0.85 | ALDH1A1 (0.62) | ALDH1A1NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL2338130 | 0.85 | ALDH1A1 (0.77) | ALDH1A1NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL29992015 | 0.84 | ALDH1A1 (0.69) | ALDH1A1NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL329831 | 0.84 | ALDH1A1 (0.56) | ALDH1A1NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL329832 | 0.84 | ALDH1A1 (0.56) | ALDH1A1NPC1RAB9AMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130317041-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-11-28 | — | — | US | disclosed |
| US-8536182-B2 | Benzylpiperazine derivatives and their medical use | GLAXO GROUP LIMITED (GB) | 2013-09-17 | — | — | US | disclosed |
| EP-1907374-B1 | Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders | GLAXO GROUP LTD (GB) | 2012-08-22 | — | — | EP | disclosed |
| EP-2441763-A1 | Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders | Glaxo Group Limited (GB) | 2012-04-18 | — | — | EP | disclosed |
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | KOWA CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | KOWA CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20090054456-A1 | BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2009-02-26 | — | — | US | disclosed |
| EP-1907374-A2 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007012479-A2 | BENZYLPIPERAZINE DERIVATES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2007-02-01 | — | — | WO | disclosed |
| US-20060040986-A1 | Erythropoietin production accelerator | KOWA CO., LTD. (JP) | 2006-02-23 | — | — | US | disclosed |
| EP-1568691-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | Kowa Co., Ltd. (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20050176764-A1 | Medicine for treating cancer | KOWA CO., LTD (JP) | 2005-08-11 | — | — | US | disclosed |
| US-6867221-B2 | Cyclic amine compounds and pharmaceutical composition containing the same | KOWA CO., LTD. (JP) | 2005-03-15 | — | — | US | disclosed |
| EP-1494670-A1 | MEDICINE FOR TREATING CANCER | Kowa Co., Ltd. (JP) | 2005-01-12 | — | — | EP | disclosed |
| EP-1422219-A1 | CYCLIC AMINE COMPOUND | Kowa Co., Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-20040010147-A1 | Cyclic amine compounds and pharmaceutical composition containing the same | KOWA CO., LTD. (JP) | 2004-01-15 | — | — | US | disclosed |
| WO-2003086397-A1 | MEDICINE FOR TREATING CANCER | KOWA CO., LTD. (JP) | 2003-10-23 | — | — | WO | disclosed |
| US-6605620-B1 | Such as 4-(N-(4-Methoxyphenyl)-N-(3-(3,4,5-trimethoxy-phenyl)-benzoylamino)-1-((2 -(3,4,5-trimethoxyphenyl)pyridin-4-yl)-methyl)piperidine; treatment and prevention of cell adhesion or infiltration | KOWA CO., LTD. (JP) | 2003-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176764-A1 | Medicine for treating cancer | HDAC4, HDAC3, NR4A3 | ALDH1A1 1788/4885NPC1 804/4885RAB9A 4393/4885 |
| US-20060040986-A1 | Erythropoietin production accelerator | EPOR, GHRHR, ARL1 | ALDH1A1 2626/4885NPC1 3842/4885RAB9A 4136/4885 |
| US-20090054456-A1 | BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE | GPR68, GPR88, GPR55 | ALDH1A1 1817/4885NPC1 840/4885RAB9A 2456/4885 |
| US-20130317041-A1 | COMPOUNDS | GPR68, GPR88, GPR35 | ALDH1A1 1802/4885NPC1 615/4885RAB9A 1747/4885 |
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | EPOR, GHRHR, ARL1 | ALDH1A1 2626/4885NPC1 3842/4885RAB9A 4136/4885 |
| US-20040010147-A1 | Cyclic amine compounds and pharmaceutical composition containing the same | HRH3, HRH4, CNKSR1 | ALDH1A1 3386/4885NPC1 1367/4885RAB9A 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.